Cullinan Therapeutics (CGEM) EPS (Weighted Average and Diluted) (2021 - 2023)
Historic EPS (Weighted Average and Diluted) for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$28.97.
- Cullinan Therapeutics' EPS (Weighted Average and Diluted) fell 489482.76% to -$28.97 in Q4 2023 from the same period last year, while for Dec 2023 it was -$32.12, marking a year-over-year decrease of 144957.98%. This contributed to the annual value of -$27.78 for FY2024, which is 1351.18% up from last year.
- Per Cullinan Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$28.97 for Q4 2023, which was down 489482.76% from -$0.92 recorded in Q3 2023.
- Over the past 5 years, Cullinan Therapeutics' EPS (Weighted Average and Diluted) peaked at $3.77 during Q2 2022, and registered a low of -$28.97 during Q4 2023.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$2.84, with a median of -$0.58 in 2022.
- Per our database at Business Quant, Cullinan Therapeutics' EPS (Weighted Average and Diluted) soared by 114722.22% in 2022 and then plummeted by 489482.76% in 2023.
- Quarter analysis of 3 years shows Cullinan Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.76 in 2021, then rose by 23.68% to -$0.58 in 2022, then tumbled by 4894.83% to -$28.97 in 2023.
- Its EPS (Weighted Average and Diluted) stands at -$28.97 for Q4 2023, versus -$0.92 for Q3 2023 and -$0.8 for Q2 2023.